Susan Halabi Selected Research

Hormones

09/2008	A Phase II Study of Estramustine, Docetaxel, and Exisulind in Patients with Hormone- Refractory Prostate Cancer: Results of Cancer and Leukemia Group B Trial 90004.
02/2008	Second-line Chemotherapy for Advanced Hormone-refractory Prostate Cancer.
07/2006	Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
03/2006	Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
08/2005	Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
07/2005	Menopausal hormones and risk of ovarian cancer.
04/2005	Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.
03/2005	The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
09/2004	9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
08/2004	Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
12/2003	A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
04/2003	Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
02/2002	Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.

Articles by Research Topic

Disease

19	Prostatic Neoplasms (Prostate Cancer) 09/2008 - 08/2002
15	Neoplasms (Cancer) 09/2008 - 02/2002
14	Leukemia 09/2008 - 02/2002
6	Ovarian Neoplasms (Ovarian Cancer) 03/2008 - 03/2003
3	Carcinoma (Carcinomatosis) 01/2008 - 02/2002
2	Adenoma (Adenomas) 01/2008 - 03/2003
2	Renal Cell Carcinoma (Grawitz Tumor) 07/2006 - 04/2004
1	Pain (Aches) 05/2008
1	Multiple Myeloma 06/2007
1	Kidney Neoplasms (Kidney Cancer) 09/2006
1	Colorectal Neoplasms (Colorectal Cancer) 03/2003

Drug/Important Bio-Agent (IBA)

13	HormonesIBA 09/2008 - 02/2002
2	Estramustine FDA Link 09/2008 - 12/2003
2	docetaxel (Taxotere)FDA Link 09/2008 - 12/2003
2	gemcitabine FDA Link 01/2008 - 09/2006
2	Ketoconazole (Nizoral)FDA LinkGeneric 04/2007 - 03/2004
2	Androgen Receptors (Androgen Receptor)IBA 03/2007 - 07/2003
2	Progesterone Receptors (Progesterone Receptor)IBA 12/2004 - 03/2003
1	sulindac sulfone (exisulind)IBA 09/2008
1	Cyclin EIBA 03/2008
1	Testosterone (Sustanon)FDA LinkGeneric 03/2008
1	CytokinesIBA 01/2008
1	gefitinib (Iressa)FDA Link 01/2008
1	Cisplatin (Platino)FDA LinkGeneric 01/2008
1	DiphosphonatesIBA 06/2007
1	capecitabine (Xeloda)FDA Link 09/2006
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 03/2006
1	Chromogranin AIBA 08/2005
1	polyalanineIBA 05/2005
1	TGF-beta type I receptorIBA 05/2005
1	Interleukin-6 (Interleukin 6)IBA 03/2005
1	9-nitrocamptothecinIBA 09/2004
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2004
1	bevacizumab FDA Link 04/2004
1	Interferon-alpha (Interferon Alfa)FDA Link 04/2004
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2003
1	Carboplatin (JM8)FDA LinkGeneric 12/2003
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/2003
1	Suramin (Suramin Sodium)IBA 08/2002
1	Mitoxantrone (Novantrone)FDA LinkGeneric 02/2002

Therapy/Procedure

4	Castration 05/2008 - 11/2005
2	Drug Therapy (Chemotherapy) 02/2008 - 09/2004
1	Prostatectomy (Retropubic Prostatectomy) 02/2007
1	Stem Cell Transplantation 07/2006